16:55:46 EDT Thu 09 Jul 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Viemed Healthcare Inc
Symbol VMD
Shares Issued 38,486,772
Close 2020-05-04 C$ 8.88
Recent Sedar Documents

Viemed earns $4.24-million (U.S.) in Q1 2020

2020-05-04 18:39 ET - News Release

Mr. Casey Hoyt reports

VIEMED HEALTHCARE ANNOUNCES FIRST QUARTER 2020 RECORD FINANCIAL RESULTS

Viemed Healthcare Inc. has released its financial results for the three months ended March 31, 2020.

Operational highlights (all dollar amounts are USD):

  • Net revenues for the quarter ended March 31, 2020 were $23.8 million, an increase of 31% over net revenues reported for the comparable quarter ended March 31, 2019. Current quarter revenues included approximately $1 million of product sales related to the ongoing COVID-19 pandemic.
  • The Company grew its active ventilator patient base for the quarter ended March 31, 2020 by approximately 25% as compared to the prior year's comparable quarter and 3% over the fourth quarter of 2019.
  • Net income for the quarter ended March 31, 2020 totaled approximately $4.2 million, a 117% increase as compared to the quarter ended March 31, 2019.
  • Adjusted EBITDA for the quarter ended March 31, 2020 totaled approximately $7.9 million, a Company record, and a 76% increase as compared to the quarter ended March 31, 2019. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.
  • During May, the Company extended the expiration date of its existing $10 million line of credit with Hancock Whitney Bank to May 1, 2023.
  • The Company expects to generate net revenues of approximately $42 million to $44 million during the second quarter of 2020, including approximately $20 million of product sales related to the ongoing COVID-19 pandemic.

"We believe the first four months of the year have demonstrated how important the Viemed mission is to the future of our country's healthcare system," said Casey Hoyt, Viemed's CEO. "Our clinicians have come through to share their expertise with others to assist with COVID-19 solutions. In addition, we have established long-term relationships with hospitals and physicians that we expect will only be strengthened in the future as we continue to do our part in supplying ventilators and keeping hospital beds free for the patients who have become ill with the coronavirus."

Conference Call Details

The Company will host a conference call to discuss first quarter results on Tuesday, May 5, 2020 at 11:00 a.m. EST.

The call-in numbers for participants are:

  • US Toll Free: 1-800-548-4713
  • International Toll Free: 1-323-794-2093
  • Meeting ID Number: 4508551

Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)

                                              (Unaudited)
                                                                 Three Months Ended March 31,
                                                                    2020               2019 
 
Revenue                                                        $    23,806      $   18,115  
                                                                                           
Cost of revenue                                                       8,253          5,041 
                                                                                           
Gross profit                                                   $     15,553    $    13,074 
                                                                                           
Operating Expenses                                                                         
Selling, general and administrative                                  10,577          9,460 
Research and development                                                174            234 
Stock-based compensation                                              1,151            880 
Depreciation                                                            205            129 
(Gain) loss on disposal of property and equipment                    (1,169)            56 
Income from operations                                         $      4,615    $     2,315 
                                                                                           
Non-operating expenses                                                                     
Unrealized loss on warrant conversion liability                           -            169 
Loss from equity method investment                                       27             24 
Interest expense, net of interest income                                158             26 
                                                                                           
Net income before taxes                                               4,430          2,096 
Provision for income taxes                                              187            138 
                                                                                           
Net income                                                     $      4,243    $     1,958 
                                                                                           
Other Comprehensive Income                                                                 
Change in unrealized loss on derivative instruments, net of tax        (312)             - 
Other Comprehensive Loss                                       $       (312)   $         - 
                                                                                           
Comprehensive Income                                           $      3,931    $     1,958 
                                                                                           
Net income per share                                                                       
Basic                                                          $       0.11    $      0.05 
Diluted                                                        $       0.11    $      0.05 

ABOUT VIEMED HEALTHCARE, INC.

Viemed, through its indirect wholly-owned subsidiaries Sleep Management, L.L.C. and Home Sleep Delivered, L.L.C., is a home medical equipment supplier that provides post-acute respiratory care services in the United States. Sleep Management, L.L.C. focuses on disease management and improving the quality of life for respiratory patients through clinical excellence, education, and technology. Its service offerings are based on effective home treatment with respiratory care practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Home Sleep Delivered, L.L.C. focuses on providing in-home sleep testing for sleep apnea sufferers.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.